FDA Office of Acquisition and Grant Services

The Department of Health and Human Services Food and Drug Administration Office of Acquisition and Grant Services is a civilian sub-agency within FDA that executes procurement and grant-making on behalf of the broader agency's centers and laboratories. FDA's acquisition footprint spans laboratory equipment, software systems, analytical instruments, consulting services, and specialized supplies supporting regulatory science and product-testing operations across multiple FDA centers.

No recent contract award data is recorded against the agency in the source material. The agency conducts active and ongoing procurement across its centers and regional laboratories. Representative recent contract opportunities (posted in mid-to-late September 2026) include analytical and laboratory equipment: a benchtop freeze dryer system due September 28, an environmental chamber due September 25, a Fourier Transform Infrared Spectrometer due September 22, a 2D High-Density Multi-Electrode Array Electrophysiology Platform due September 23, and chromatography systems (Vanquish Neo and Ion Chromatography) due September 21. The agency also solicits software and services, including a Total Small Business set-aside IDIQ for ThinkTrends Software Implementation and Support (custom computer programming services) due September 28, subscription-based market intelligence and IP analytics search-engine access due September 22, and rapid nicotine pouch data analysis services for the Center for Tobacco Products due September 21. A sole-source award is anticipated to OrganoTherapeutics SARL for human iPSC-derived hindbrain organoid functional assay services supporting drug-evaluation research. One competitive 8(a) Special Notice for Vaccine Adverse Event Reporting System (VAERS) and Safety Monitoring Support was posted September 10 with a due date of September 18. Most equipment solicitations are unrestricted competitive procurements using Lowest Price Technically Acceptable award criteria; several are brand-name-or-equal (BNE) or brand-name (BN) acquisitions for FDA laboratory centers and specialty programs.